Search Results

Should you get both vaccinations? Yes, says an infectious disease doctor with the U.S. National Foundation for Infectious Diseases.

https://www.csl.com/we-are-csl/vita-original-stories/2021/protecting-yourself-from-covid-19-and-influenza

a self-amplifying mRNA COVID-19 self-amplifying mRNA technology The second trend is reduced rates of vaccine, for individuals 18 years and that CSL hopes will lead to the next immunisation following the pandemic, older, received regulatory approval from generation COVID-19 vaccine.

https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf

The agreement grants access to Arcturus Therapeutics' late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology, which recently reported results from a large COVID-19 Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile.

https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics

By securing access to these flu vaccines, if a pandemic is declared by the WHO, we are reinforcing our commitment to protecting health and being prepared and ready to act in the face of emerging public health threats" commented The Honourable Marjorie Michel, Minister of Health.

https://newsroom.csl.com/2026-03-05-Canada-and-CSL-Seqirus,-a-Global-Leader-in-Influenza-Vaccines,-agree-on-new-Pandemic-Preparedness-Contract

It has developed a COVID-19 vaccine candidate and has recently reported results from a large Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile.

https://newsroom.csl.com/2022-11-01-CSL-Enters-Licensing-Agreement-with-Arcturus-Therapeutics-for-Next-Generation-mRNA-Vaccine-Technology

As a global leader in the protection of public health and one of the largest influenza vaccine providers in the world, CSL Seqirus is committed to preventing infectious diseases, like influenza and COVID-19, and is a transcontinental partner in pandemic preparedness.

https://newsroom.csl.com/2025-04-29-CSL-Seqirus,-a-Global-Leader-in-Pandemic-Preparedness-and-Outbreak-Response,-Signs-an-Agreement-with-the-European-Commission-to-Support-Pandemic-Preparedness-Plans

Alpha 1 Antitrypsin (AAT) Deficiency is a genetic condition which can affect the lungs and liver. Learn more about this condition and what it means for patients.

https://www.csl.com/patients-public-health/rare-and-serious-diseases/alpha-1-antitrypsin-deficiency

As a clinician, I look forward to being able to provide a new treatment option that may help patients treated with HEMGENIX become free from the regular infusion schedule that many people living with hemophilia B rely on to protect them from the debilitating effects of the condition.

https://newsroom.csl.com/2022-11-22-U-S-Food-and-Drug-Administration-approves-CSLs-HEMGENIX-R-etranacogene-dezaparvovec-drlb-,-the-first-gene-therapy-for-hemophilia-B

If you're immunocompro- mised, you won't be the one caring for a child with the flu or COVID-19.

https://www.csl.com/-/media/csl/more-than-a-patient-book/more-than-a-patient-by-jodi-taub.pdf

CSL respectCSL to Seqirus the CSL UK Group's own and CSL manufacture Seqirus thepandemic differentiated preparedness, includingSeqirus is focused acrosson developing all age groups differentiated in expanded vaccines ® operations.product CSL FLUAD Seqirus, which has corporateis an adjuvanted the product UK, Canada, for the elderlySwitzerland protecting and againstmarkets respiratory is a viruses,strategic influenza priority forand CSL COVID-19 hubsmarket.

https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2024-25.pdf